Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMUNOR versus placebo for recurrent vulvovaginitis
2015-001472-22Phase 3Completed
- Sponsor
- Imunomedica
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vulvovaginitis comparing IMUNOR with Placebo (2 arms). Primary endpoint: Reduction in number of vulvovaginitis episodes over 12 months. Started Jun 2015; status: completed.
02
Drugs
inosine pranobex
03
Conditions
Vulvovaginitis
Beyond the preview
Go deeper on 2015-001472-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001472-22.